LOUMEAU ERIC J 4
4 · ANAPTYSBIO, INC · Filed Dec 18, 2025
Insider Transaction Report
Form 4
ANAPTYSBIO, INCANAB
LOUMEAU ERIC J
CHIEF LEGAL OFFICER
Transactions
- Exercise/Conversion
Common Stock
2025-12-16$14.02/sh+5,000$70,100→ 14,088 total - Exercise/Conversion
Common Stock
2025-12-16$20.16/sh+7,500$151,200→ 21,588 total - Sale
Common Stock
2025-12-16$44.68/sh−8,305$371,031→ 13,283 total - Sale
Common Stock
2025-12-16$45.24/sh−4,195$189,769→ 9,088 total - Exercise/Conversion
Common Stock
2025-12-17$14.02/sh+10,000$140,200→ 19,088 total - Sale
Common Stock
2025-12-17$46.00/sh−10,000$460,000→ 9,088 total - Sale
Common Stock
2025-12-18$46.99/sh−141$6,626→ 8,947 total - Exercise/Conversion
Employee Stock Option (right to buy)
2025-12-16−5,000→ 63,000 totalExercise: $14.02Exp: 2029-12-05→ Common Stock (5,000 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2025-12-16−7,500→ 0 totalExercise: $20.16Exp: 2030-07-12→ Common Stock (7,500 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2025-12-17−10,000→ 53,000 totalExercise: $14.02Exp: 2029-12-05→ Common Stock (10,000 underlying)
Footnotes (5)
- [F1]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.12 to $45.11 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.13 to $45.34 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The stock option is fully vested.
- [F5]In addition to the options to purchase a total of 53,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 414,810 shares of common stock, which options vest according to their terms.